Lead. Post-traumatic stress disorder remains one of the most challenging neuropsychiatric conditions to treat, particularly because its core symptoms, hyperarousal, nightmares, fear extinction deficits, and sleep disruption, feed into one another in a self-reinforcing loop that standard pharmacotherapy often fails to break. A scoping review published July 2 in Military Medicine (PMID: 42391109) now points toward an unexpected candidate for disrupting that loop: the orexin system. By reviewing 11 preclinical and clinical studies on dual orexin receptor antagonists (DORAs) and selective receptor antagonists, researchers from Tripler Army Medical Center present a case that blocking orexin signaling may simultaneously address fear extinction, REM sleep regulation, hyperarousal, and even cellular stress resilience, a combination of effects few single agents can claim.
Key Points and Framework. The orexin (also called hypocretin) system is a pair of neuropeptides produced exclusively in the lateral hypothalamus that project widely throughout the brain to regulate arousal, wakefulness, stress reactivity, and reward processing. Dysregulation of this system has been implicated in anxiety disorders, addiction, and sleep pathology, all features that overlap with PTSD. The review, led by Connor Lewis and John Eric M. Novosel-Lingat, systematically examined the existing evidence for orexin antagonists as a therapeutic strategy in PTSD, drawing on studies ranging from rodent fear-conditioning paradigms to one randomized clinical trial in human patients.
Suvorexant and Clinical Evidence. The only clinical trial included in the review tested suvorexant, an FDA-approved dual orexin receptor antagonist indicated for insomnia, in patients with PTSD. The results were instructive in two directions. On one hand, the drug produced clear enhancements in REM sleep architecture and, notably, most patients experienced remission of trauma-related nightmares, a symptom that is notoriously pharmacoresistant. On the other hand, a strong placebo response limited the statistical separation between groups, making it difficult to attribute the improvements definitively to the drug. The authors are careful to note that while the signal is encouraging, larger, well-controlled trials are needed before clinical recommendations can be made.
Preclinical Evidence for Fear Extinction. The preclinical work is where the case for orexin antagonism builds most strongly. In rodent models of stress exposure, suvorexant accelerated fear extinction, the process by which a learned fear response diminishes when the threat is no longer present, and reduced hyperarousal, avoidance behaviors, and anxiety-like phenotypes. The effect appears to be mediated at least in part through the basolateral amygdala, a key node in fear circuitry. Selective OX1R antagonists, such as the experimental compound SB334867, similarly facilitated fear extinction and reduced freezing behavior when administered systemically or directly into the amygdala.
What makes these findings compelling from a mechanistic standpoint is their specificity. The review reports that reduced orexin signaling was consistently associated with a resilience phenotype across multiple experimental models. In other words, animals with lower orexin tone or those given orexin receptor antagonists behaved in ways that resemble natural resilience to stress, they extinguished fear faster, showed less startle reactivity, and maintained more normal sleep-wake cycles even after trauma exposure.
Beyond Behavior: Cellular Stress Resilience. The review also touches on emerging evidence that orexin antagonism may confer benefits at the cellular level. Early studies indicate that blocking orexin signaling can normalize mitochondrial function and modulate mTOR pathway activity, both of which are implicated in the cellular response to chronic stress. While these findings are preliminary, they hint at a possible mechanism through which orexin antagonists might produce not just symptomatic relief but also restoration of neurobiological homeostasis in individuals with PTSD.
Implications. The proposition that a single class of drugs could improve fear extinction, stabilize sleep, dampen hyperarousal, and promote cellular resilience is a striking one, and it comes with important caveats that the authors do not gloss over. The evidence base is still predominantly preclinical, with only one clinical trial in humans and that trial compromised by a robust placebo response. The heterogeneity of the reviewed studies (different antagonists, different doses, different rodent strains and stress protocols) makes it difficult to draw firm dose-response or comparative efficacy conclusions.
Nevertheless, the clinical need is acute. PTSD affects a disproportionate number of active-duty military personnel and veterans, the very population served by the journal and the authors’ institution. Current first-line pharmacotherapies, selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors, show modest effect sizes and do not reliably address sleep disturbance or nightmares as a primary outcome. The orexin system offers a fundamentally different entry point into PTSD pathophysiology, one that targets the arousal and sleep circuitry directly rather than modulating monoamine signaling broadly.
For clinicians and researchers, the review suggests two near-term priorities. First, the design of adequately powered clinical trials with orexin antagonists in PTSD should account for placebo response by using objective sleep measures (polysomnography, actigraphy) and possibly enrichment strategies that select patients with objective REM disruption. Second, the preclinical data support further investigation of selective OX1R antagonists, which may offer a more targeted approach than dual antagonists, potentially avoiding some of the daytime sedation associated with DORAs.